European Commission Grants Orphan Drug Status For AmpliMed Corporation's Amplimexon(R) For The Treatment Of Ovarian Cancer
TUCSON, Ariz.--(BUSINESS WIRE)--Jan. 11, 2006--AmpliMed Corporation today announced that the European Commission has approved the recommendation of the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) to grant an orphan medicinal product designation for Amplimed's lead drug, Amplimexon(TM) (imexon inj.) for the treatment of ovarian cancer.